Man Achieves HIV Remission Following Rare Bone Marrow Transplant from Brother

A 63-year-old Norwegian man, referred to in medical literature as the Oslo patient, has achieved long-term remission from HIV. The result follows a bone marrow stem cell transplant from his brother, making him one of a small number of individuals globally to reach this state.

While current antiretroviral medications can effectively control HIV by stopping the virus from replicating, they cannot completely eradicate it from the body. Because the virus remains dormant in certain cells, it typically rebounds if medication is discontinued. This case provides researchers with critical data on the potential for a full cure.

The Role of the Stem Cell Transplant

The patient did not receive the transplant to treat HIV, but rather to treat a rare form of blood cancer. During the process, researchers from Oslo University Hospital discovered that the patient’s brother possessed a rare genetic mutation known to provide resistance to HIV.

View this post on Instagram

The procedure, termed an allogeneic hematopoietic stem cell transplantation (HSCT), involved replacing the patient’s immune system with cells from the donor. Researchers specifically tracked chimerism to determine the extent to which the donated immune cells had taken over the patient’s system.

The patient underwent the transplant at age 58. By the time he reached age 63, he remained in remission. According to the research published in the journal Nature Microbiology on April 13, 2026, all traces of functioning HIV DNA were cleared four years after the transplant.

The Genetic Mechanism of Resistance

The success of the remission is attributed to a specific genetic mutation called CCR5 delta 32. This mutation disables a protein on the surface of immune cells that HIV typically exploits to enter and infect the cell.

In this case, the patient’s brother carried two copies of the CCR5 delta 32 mutation. This genetic profile effectively locks the virus out of the cells that would normally serve as its primary targets, preventing the virus from establishing a new infection in the remodeled immune system.

The rarity of this occurrence is highlighted by the statistical probability of such a match. A sibling has a 25% chance of being a transplant match, but the frequency of the CCR5 delta 32/32 genotype is only around 1% in northern European populations.

Clinical Timeline and Outcomes

The patient’s recovery and viral suppression followed a specific timeline:

• The patient received the allogeneic hematopoietic stem cell transplantation at age 58.
• Two years after the HSCT, the patient was able to stop taking his HIV medication.
• Four years after the HSCT, all traces of functioning HIV DNA were found to have been cleared.
• At five years post-HSCT, there was still no evidence of viral rebound.

Significance for HIV Research

This case differs from previous instances of HIV remission following stem cell transplants because the donor was a sibling rather than an unrelated donor. This adds a new layer of evidence to the existing knowledge base regarding potential cures.

The case of the Oslo patient contributes valuable evidence to the existing knowledge base regarding HIV cure cases. This and other studies on HIV cure enhance our understanding of HIV pathology, molecular mechanisms, and predictive biomarkers that may be of broader interest, extending beyond patients treated with allogeneic HSCT.

Nature Microbiology

By studying the molecular mechanisms that allowed the Oslo patient to clear the virus, researchers hope to identify biomarkers and pathways that could lead to broader therapeutic applications for other patients.